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Abstract 
 
 In the following study, we researched how Corporate Social Responsibility 
related initiatives of a company in the pharmaceutical sector are linked with its 
financial performance, as portrayed by the net earnings, and its stock exchange 
performance, as portrayed by its stock price.  
 In the beginning of our study, we have provided a thorough background of 
previously conducted CSR studies in every industry, followed by a focus in the 
pharmaceutical industry related studies. Our research has shown both negative and 
positive results, with the positives ones clearly outnumbering the negative ones.   
 In the second part of our study we have regressed the CSR data collected by 
CSRHub database with the financial data, as extracted by ThompsonOne database 
for a total of 196 companies and data between 2008 and 2013. In order to validate 
results, we also used data from 2008 up to 2012 for 80 companies, using the KLD 
database by pairing variables used in the previous regressions. Lastly, we have used 
the ranking of the 20 companies from Accesstomedicineindex.org for years 2008, 
2010 and 2012, used linear interpolation to calculate middle points and once again 
regressed them with the financial data. 
 Of the 29 variables found significant in our study, results in general have 
shown a positive relationship between most variables with very few exceptions. 
However, once those variables have been compared with the intercept in each 
regression, the results have been found to be rather negligent in absolute terms. 
Nonetheless, we believe that any CSR related initiative should not based on 
economic advancement of a company per se, but in providing a better welfare for 
people in developing countries. 
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Chapter 1 
 
1.1 General Introduction 
In the first chapter we will provide some definitions essential for our study. A 
short analysis of the Corporate Social Responsibility is also presented in the current 
global and regional situation as it relates to the topic. Next it will look at the 
statement of the problem which led to conceptualization of the study and also 
analyse the objectives of the study that will be our guide for research. After the 
objectives it will provide the scope under which this study will be centred upon. Next 
it will look at the significance of this study providing reasons as to why it should be 
carried out. In the end we will refer to the limitations that were experienced in the 
process of carrying out this study before providing a short summary of what was 
discussed in the whole of this chapter in the conclusion. 
 
1.2 Corporate Social Responsibility overview 
 Corporate Social Responsibility, which is usually referred as CSR (which we 
will use for the rest of our research), is defined by businessdictionary.com as " A 
company’s sense of responsibility towards the community and environment (both 
ecological and social) in which it operates. Companies express this citizenship (1) 
through their waste and pollution reduction processes, (2) by contributing 
educational and social programs and (3) by earning adequate returns on the 
employed resources." However this definition does not exhaust the broad scope of a 
company's CSR. Companies nowadays, even though sometimes obliged by the law to 
do so, care besides the environment and community, also for their workforce (as this 
might be expressed by respecting employee rights, equal opportunities despite race 
or gender, fair compensations etc.) as well as their corporate governance ethics, 
which may be portrayed by transparency towards the stakeholders, ethical decisions 
and so on. 
 Even though concerns on the social responsibility of companies started as 
early as in the 1930s (Barnard, 1938 - Clark, 1939) and the 1940s (Kreps, 1940), CSR 
as a business notion gained popularity in the 1960s and 1970s. A special mention has 
to be made to Kevin Davis, whose research (Davis, 1960 - Davis, Bloomstrom, 1966 - 
Davis, 1967 - Davis, 1973)  boomed CSR as an academic field of study and as a 
strategic planning for businesses.  
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1.3 Statement of the research problem 
 CSR has become nowadays an integral part in the business world. Every kind 
of company worries about their impact on the community and the perception of 
people about them. So, do pharmaceutical companies make an effort to behave 
responsibly? This question has already been answered in 2012 by 32.582 
respondents and the results were 50% Yes and 50% No. 
 That does not provide any real value for decision makers in pharmaceutical 
firms. Certainly those numbers should have been in favour of "Yes" respondents, but 
we believe that the real question of any executive is "Does CSR payoff?". In a 
dynamic economic environment, where crisis is still undermining the efforts of many 
companies, executives point of view on CSR is the same as the erection of a new 
building or the takeover of a competitor. Will the project have a positive Net Present 
Value? If I spend an extra million Euros to make my financial reports more 
transparent will investors push the price of my stock higher? Will that new ecological 
energy consumption investment allow me to appear more eco-friendly in my 
consumers? As Smith (2003) suggests there two schools of thought when it comes to 
why firms perform CSR projects. The first one, maybe the most romantic of the two, 
is the desire to do good and payback to the society, typically called the normative 
case by academics. The other one, the business case, is the self-interest of firms to 
do CSR and expect a payoff for it.  
 Even thought these questions are applicable to most industries, our focus lies 
on the pharmaceutical sector. Our choice of sector was made due to the importance 
of it as people seem to spend more and more on it. Healthcare expenditure rose 
from 8.7% of the total GDP in 2005 to 9.5% in 2012 (peaked at 9.7% in 2009). 
(Source: OECD Health Data: Health expenditure and financing: OECD Health Statistics 
database). Also, the life expectancy of people is constantly rising due to 
technological developments in the sector. To be more specific according to OECD 
data, the average life expectancy rose with a steady rate from 78,5 years on 2005 to 
80.0 years on 2012 (study of 39 countries). Lastly, but maybe the most important is 
the profitability of the sector being the highest with an average of 17.10% as of May 
2014, when the second best was as low as 14.45% (financial sector). 
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1.3.1 Research questions 
 The purpose of our study as stated above would be to reach a conclusion on 
whether practicing CSR has a positive payoff for pharmaceutical companies. The 
main categories under examination that we will link to payoff are as follows: 
• Community 
• Corporate Governance 
• Environment 
• Employees 
 Each of the aforementioned categories will have 3 separate sub-categories. 
For instance on "Employees" category, we will examine "compensation", "diversity & 
labor rights" and "training & safety". That will allows us to have a more detailed 
picture of what works and what doesn't in order to reach to a conclusion not only 
per category, but also in CSR as a total. 
 
1.4 Research gap 
 CSR is a quite extensively researched topic in the academic community. More 
specifically, by going through the literature regarding CSR and pharmaceutical 
companies, we have found researches on consumers perception (European 
Commission, 2012), as well as employee perception (Min et al, 2013), a study with 
140 responders.  The latest quantitative research on payoff was back in 2004 
(Tsoutsoura) , however since the focus was not on pharmaceutical firms the 
pharmaceutical firms of the study were only 32 out of the total 422 the research was 
based on.  
 We believe that there is a gap on quantitative analysis on the pharmaceutical 
sector between the CSR employed by each company and the payoff for them. Our 
focus on the pharmaceutical firm, with the bigger data set we will utilize will allow us 
to have more detailed and up-to-date results, as our examination period will be after 
2008. 
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1.5 Significance of research 
 We strongly believe that our study is quite significant, because it will shed a 
light on whether executives should keep CSR on top of their agendas from a financial 
- profitability point of view. Thus, they will be able to benchmark their results from 
CSR projects and compare them to other companies within their industry.  
 Healthcare sector is a very important sector with a market capitalization of 
81.3 trillion USD. Our focus will be on pharmaceuticals, which comprise 
approximately 75% of the sector. With their rapid growth and the constant 
technological developments, this sector will keep on being the most profitable 
compared to others. 
 
1.5.1 Expectations of the research 
 Our literature review as we will present extendedly on the second chapter of 
the research is not clear on the results. Most studies tend to present a positive 
payoff for CSR practices in different sectors, however there are numerous others 
that have as results the negative scenario. 
 Therefore, we expect our results to be positive, but not strongly significant. 
We do believe though that spending a significant amount of money in order to keep 
everyone in your workforce happy, trained and safe does not have a significant 
effect on profitability. Employees are typically under the impression that they are 
underpaid therefore an increase in their salary or an extra hour of training will 
probably lead to a disproportionate effect on productivity favoring the employee 
rather than the employer.  
 Regarding "Corporate Governance" category, we expect the results there to 
be insignificant. We feel that ethics is a rather subjective term and each individual 
understands it in a different kind of way. Therefore, have an ethical leadership might 
or might not have positive effects on the course of the company. 
 Lastly, we expect the other two categories under examination, 
"environment" and especially "community" to have a positive and significant effect 
on a positive payoff for pharmaceutical companies. More specifically, our 
expectations on the "community" category is a highly significant positive variable. It 
seems that when it comes to drugs, people are more sensitive on which companies 
try to give back to their communities, while the rest of them is portrayed as "evil" 
corporations. 
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1.6 Definition of key terms 
Corporate Social Responsibility - Defined in first paragraph of chapter 1.2 
Pharmaceutical industry - Part of the healthcare sector, companies that belong in the 
industry that develops, produces and promotes drugs, licensed and registered for 
medicinal use. 
Payoff - Any kind of monetary or non-monetary (i.e. brand recognition) gain, a 
company benefits from undertaking a specific project. In our case this project is 
defined as any CSR related activity. 
 
1.7 Dissertation structure 
 Dissertation has been structured in such a way to provide a comprehensive 
and holistic view of the research. It is segmented in five different chapters. 
 In the first one, we provide several introductory elements regarding the 
study. In the second one, there is more detailed literature review of related past 
researches, papers, articles and books on the subject. In the third one, we provide an 
thorough analysis of our data set, the tools and the methodology we used. In the 
fourth one, we provide our results based on the analysis, while in the last one we 
conclude and analyze the results given. 
  
1.8 Chapter summary 
 In the first chapter, we began with an introduction of our study. Afterwards, 
we have provided a short historical overview and the definition of the Corporate 
Social Responsibility. We have analytically stated the research problem as it is the 
linkage of the payoff and the CSR practices, simultaneously stating why we chose the 
pharmaceutical sector to study and why our study is of significant value. We have 
provided our expectations on the research questions and defined some key terms 
that we will repeatedly use during our study. Lastly, we have provided to the readers 
a short analysis of the dissertation structure. 
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Chapter 2 
 
2.1 Literature Review 
 In the following chapter we will provide the literature review of our research. 
We will provide findings of past researches, articles, books and papers regarding the 
linkage between payoff and CSR initiatives. Additionally, we will also discuss the 
background of the CSR findings and lastly we will discuss some information as 
regards to the pharmaceutical industry, as well as common CSR projects. 
 
2.2 Scandals in the pharmaceutical industry 
 Our focus on pharmaceuticals has to do with the immense amount of 
publicity exposed to those companies in regards to their dishonest practices. Even 
though any kind of exposure allows a company to make their brand name more 
recognizable - after all there is no such thing as bad publicity - when it comes to 
pharmaceuticals they try to avoid any such news for their products. The examples of 
dishonest communication of medicine or unethical practices are numerous. 
 GlaxoSmithKlein one of the leading pharmaceutical firms, based and listed in 
England settled to pay a 3 $ billion fine in 2012. GSK pleaded guilty for promoting 
two of its antidepressants, Wellbutrin and Paxil, for unapproved uses. They were 
also liable for failing to report safety data for Avandia, an antidiabetic drug (Source: 
www.justice.gov). 
 However, GSK was not the only pharmaceutical company to be fined in the 
billion dollar range. Three more companies, Pfizer, Abbott Laboratories and Eli Lilly, 
have been fined 2.3 $ billion, 1.5 $ billion and 1.4 $ billion respectively for similar 
reasons (Source: www.justice.gov). Other fines, less than the one billion dollars are 
too many to list. It is calculated than in the past few years pharmaceutical firms have 
been fined over 13 $ billion. 
 Nonetheless, pharmaceuticals are not only known for false advertisement or 
misreporting. There have been far more serious allegations, such as Pfizer's clinical 
trial in Nigeria in 1996. It has been concluded by Nigerian medical experts that Pfizer 
in 1996 tested an unapproved drug on children with brain infections (Stephens, 
2006). 
 Last but not least, it is of common knowledge what happened in S. Africa 
when Nelson Mandela tried (and succeeded) to increase the availability and 
affordability of AIDS related drugs. Even though his country was sued by 39 (!) 
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different firms, the publicity the matter took was enough to press them to drop the 
lawsuit unconditionally 3 years later (Sidley, 2001). 
 
2.3 CSR initiatives in pharmaceutical industry 
 On the other hand, it seems that pharmaceuticals have embraced CSR 
practices. Donating cash or drugs, developing new drugs of low commercial value 
and increasing access to them to several countries are only a few of the initiatives 
pharmaceutical executives undertake.  
 To begin with, in 2010 in the Ethical Corporation Responsible Business 
Summit, GSK CEO Witty Andrew was named Individual Leader of the Year. What he 
did was to cut down prices of drugs by 75% in undeveloped countries compared to 
developed ones, while investing 20% of profits in those countries to build healthcare 
infrastructure (Tolve, 2011). 
 Likewise, Merck provided drugs free of charge to Rwanda for HPV vaccination 
against cervical cancer. This went on for three years, but after the timeframe has 
passed, Merck has provided the same vaccines at a discounted price (Green, 2013). 
 Certainly there are no expectations for the "Big Pharma", as the major 
pharmaceutical firms often referred to, to act as charities. After all, they are 
corporations that seek out profit to survive. However, there is fine line where a 
pharmaceutical company acts as a corporate citizen, which puts people over profit 
and when the bottom line, practices such as false advertisement and testing without 
consent, begins. 
 
2.4 CSR Literature review 
 Academic studies on CSR and their results have been quite numerous and 
controversial. However, the main issue has been the lack of comparability, due to 
several different factors taken into consideration between those studies. As 
McWilliams (2006) suggests "... analysis of CSR is still embryonic, and thus 
theoretical frameworks, measurement, and empirical methods have not yet been 
resolved." Besides that, most of CSR studies have included different kind of 
industries and sectors in their research. This causes more issues than a larger set of 
data might solve. As Hatch and Godfrey expressed in 2007 "... the economic and 
technological diversity between industries, and the resource and positioning 
differences within industries, imply that firms, even those within the same industry, 
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may gain unique competitive advantages by implementing different CSRs" and they 
suggest that researchers should focus on individual industries for their research. 
 One of the most exhaustive literature reviews took place by Margolis and 
Walsh (2002). They analyzed the results of 95 published studies that took place 
between 1972 and 2001 regarding the link between a company's social and financial 
performance. Their results showed that 53% of the studies had a positive financial-
CSR relation, 24% had no relation whatsoever and only a mere 4% were reported to 
have a negative relation. The rest 19% reported mixed results that were a 
combination of the above. 
 Likewise, Orlitzsky et al (2003) have conducted a meta-analysis of 52 studies, 
which combined provided them with a total of 33.878 observations. Their findings 
suggest that " corporate virtue in the form of social responsibility and, to a lesser 
extent, environmental responsibility is likely to pay off, although the 
operationalizations of CSP and CFP also moderate the positive association".    
 A few years earlier Griffin and Mahon (1997) have examined the results from 
62 different studies. That researched was focused on the chemical industry. Results 
were once again mixed with the balance shift in favor of a positive relation. To be 
more specific, 33 of the studies have reported a positive relation, 9 have reported no 
relation and the rest (20) studies have reported a negative relation. Alike Hatch and 
Godfrey, Griffin and Mahon suggest that each industry has its own specific effects 
and individual industry studies portray better the results from such researches. 
 However, there is not only monetary gain from CSR practices. Most 
researches, including the current one, focus on the link between CSR and 
profitability or economic performance in general. Godfrey et al (2009) test the 
benefits of CSR as an "insurance-like" policy. In a sense, companies are creating 
goodwill that they redeem when a legal or regulatory action comes against them, by 
a more lenient treatment or a lower fine. However, after analyzing 178 negative 
actions (legal/regulatory) they suggest that this benefit is offered only when CSR 
practices are aimed at the society rather than a company's trading partner. 
 Lastly, Corporate Social Performance is not only determined by good CSR 
practices. There are other issues that play an integral part in the success of the 
company. Gulati (1995) and Wu (2006) both suggest that the size of a company is an 
important factor in CSR policies. It is suggested in those studies that larger 
companies usually have a bigger pool of resources willing to provide to the society, 
as well as the cost of CSR that they might have to rollover to the final consumer is 
quite insignificant compared to a smaller firm. Except for size, a healthy relation with 
the labor force might increase effectiveness and instill enthusiasm (Hamel G., 
Prahalad C. , 1994). 
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2.5 CSR as a business practice 
 CSR sensitive businesses have a constantly increasing popularity. Thus, CSR 
policies have been a major factor for investors. The proof for that is the vast number 
of indices, funds and websites that rank any kind of CSR hinted policy. 
 To begin with the most well-known ones, Dow Jones Sustainability Indices 
(DJSI) have been around for the past 15 years being the first one to be offer to 
investors in a cooperation of Standard & Poor's with RobecoSAM. As their website 
eloquently states "Corporate Sustainability is a business approach that creates long-
term shareholder value by embracing opportunities and managing risks deriving 
from economic, environmental and social developments". DSJI relies on a best-in-
class approach and companies included in the indices are constantly in the need to 
strengthen and intensify their practices in order to stay included. It has been an 
effective platform, because it has created an intense competition amongst 
companies in the same industry. Almost 3.400 companies have been invited for 
evaluation in 2014, but since the included ones will be approximately 2.500, we can 
easily understand the intensity of the competition. 
 A 2004 Mercer survey (Ambachtsheer, 2005) revealed that 89% of 
investment managers in Asia and 69% of investment managers in Europe believe 
that Socially Responsible Investment (SRI) would join the investment mainstream in 
the coming 10 years, but only 36% of investment managers in the U.S. share that 
belief. His beliefs were correct, especially if we take into consideration that their 
number is constantly increasing and 2012 Trends Report counted them to be 333 in 
2012, when they were only 173 in 2007, a whopping increase in their number (USSIF 
Foundation, 2012).We can easily assume that DSJI is not the only index that bases its 
companies selection on CSR criteria. S&P 500 Index for socially responsible firms, 
Calvert Social Index, Domini Social Index (DSI 400), TIAA-CREF Social Choice Equity 
are only a few of the hundreds of social responsible indices available to the investing 
audience in the financial world.  
 Besides funds available for investment, there are numerous other rankings 
that companies strive to be included in. One of the most important ones for the 
pharmaceutical industry is the Access to Medicines Index. Being published since 
2008 and every two years, it is an independent ranking of pharmaceutical companies 
(a specific set of the top 20 firms) based on what they do in order to increase 
availability of drugs in developing countries. Wim Leereveld, a Dutch entrepreneur 
with experience in the pharmaceutical industry initiated and published the first 
ranking in 2008, thinking that public recognition might work as a better system for 
companies to improve what they are doing. Currently, the ranking is being founded 
by the UK and Dutch governments, as well as the Bill & Melina Gates Foundation. 
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 Another important ranking is the Carbon Disclosure Project (CDP). CDP is a 
London-based non-profit organization measures, discloses, manages and shares 
environmental information data from over 4.500 companies and cities. Its focus is to 
persuade companies to disclose their impact on the environment and motivate them 
to take actions to reduce them (Carbon Disclosure Project, 2014). An alike ranking is 
the Newsweek's Green Rankings, which ranks the world's largest companies on 
corporate sustainability and environmental impact (Newsweek's Green Ranking, 
2014), as well as the Climate Counts, which tries to bring companies and consumers 
together in an attempt to address solutions around climate change by scoring 
companies on their climate impact and aware consumers of the sensitive firms 
around the globe (Climate Counts, 2014) . 
 On the human rights front there is an organization called Business and 
Human Rights Resource Centre, which tracks down human rights abuse and 
advances of companies around the world, helping the vulnerable to eradicate abuse 
(Business & Human Rights Resource Centre, 2014).  
 Lastly, there are some organizations that gather and report a collective set of 
information on CSR data. KLD Social Ratings Database and CSRHub are two such 
databanks. In our research, we have used the dataset from CSRHub as we feel the 
provided data are more extensive and easier to use. CSRHub provides a dataset 
containing more than 9.300 companies from 135 industries, gathered and ranked 
independently from more than 350 data sources, combining that information in an 
aggregated and normalized ranking. 
 
2.6 Chapter summary 
 In the second chapter of our research, we went through some critical events, 
both negative and positive, of pharmaceutical firms, which are the focus of this 
research. We have provided the theoretical framework of the CSR as it was given by 
the literature in the past years. In the end, we concluded the chapter by providing an 
analysis on current CSR business practices, such as investment mutual funds, as well 
as rankings and indices available as resources for academics and institutional 
executives. 
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Chapter 3 
 
3.1 Research introduction 
 In the following chapter , we will examine thoroughly the methodology used 
in the research , present the characteristics of companies in our data set, explain the 
questions raised and provide the tools we have used for the analysis. 
 
3.2 Methodology and tools 
 Like any research , this would also have to be undertaken by a research 
methodology appropriate for it . Research can be categorized into two different 
types: qualitative and quantitative , each of which has both advantages and 
disadvantages (Amaratunga et al . 2002; Saunders , Lewis & Thornhill 2007). 
 In our case , we believe that the most appropriate model to follow would be 
a quantitative analysis based on the data set given. Our conclusions will be drawn 
after running a regression analysis on the variables. 
 We have used Stata software in order to perform the regression analysis. 
Microsoft Office was also used in the preparation phase, prior to data analysis. 
CSRhub website and ThompsonOne database were used in order to collect the CSR 
and financial data accordingly. KLD dataset, as well as Accesstomedicineindex.org 
ranking were used to validate the CSRHub results. 
  
3.3 Data set 
 As mentioned already, our raw data was collected by CSRHub and 
ThompsonOne databases, as well as KLD and Accesstomedicineindex.org. As 
ThompsonOne, KLD and Accesstomedicineindex.org are well-known and 
indisputable databases, we will only expand on our choice of CSR raw data by 
CSRHub, which will be the basis of our analysis. 
 Even though there are several other sources for CSR data, such as Kinder, 
Lydenberg, Domini Research & Analytics or Fortune Magazine’s “Most Admired 
Companies”, we have chosen CSRHub as our data source. CSRHub is a rather new 
company founded in 2007, however it includes a much more complete list of 
companies especially in the pharmaceutical industry. In addition to that, there are 
quite a few published studies using CSRHub data (indicatively, Hughey C. and 
Sulkowski A., 2012 - Roitto A., 2013) with interesting results. 
  To be more specific, CSRHub includes monthly data since December 2008 for
252 pharmaceutical companies. As some companies do not have a complete set of 
data for this particular research, we will include the 19
criteria. 
 They assign a number from 0 up to 100 based on over 400 CSR sources for 17 
different categories with most scores ranging between 20
score, including 4 main categories, each of which includes another 3 subcategor
Weightings are unequal and are based on the validity and popularity of each source. 
The categories and their sub
Graph 1: CSRHub data categorization
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3.3.1 Data set characteristics
 The geographical 
however this quite reasonable as most pharmaceutical industries are based in USA. 
However, our sample has a very wide geographical coverage that can only add 
credibility by adding different economies, 
 The graph below shows the countries and the number of pharmaceutical 
companies represented in the current research.
Graph 2: Percentage of pharmaceutical companies in each country
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company. We have mainly based the classification of the company size on number of 
employees (firstly) and annual turnover (secondly). Therefore, we have categorized 
as "SME" any company with 249 or lower 
250-999 employees and as "Enterprise" any company exceeding 1000 employees. 
For our calculations, we used the total number of employees from any branch or 
subsidiary the company might have in a related industry.
 Then, we upgraded to "Large" any "SME" company with more than 50 million 
Euros turnover and likewise we upgraded to "Enterprise" any "Large" or "SME" 
company with more than 
Graph 3: Percentage of pharmaceutical companies by size
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 On the other side of the table, the ones with the worst overall rating were 
the Spanish Faes Farma SA, the German-based Stada Arnzeimittel AG, Gunze Limited 
based in Japan, French Virbac and the Greek Alapis, which has declared bankruptcy 
at the end of 2013. 
 
3.4 Chapter summary 
 Chapter 3, we focused around our data set. We have included the 
methodology used in the research, as well as the tools utilized to succeed. Then, we 
have provided a thorough analysis of our data set. Information given included 
categorization of the CSR data and firms size and geographic proximity. Also, we 
have elaborated on our choice of CSRHub as our main source of data. 
 
 
Photo 1: Major pharmaceutical companies  
 (Source: www.rsapharmaceuticallistservices.com) 
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Chapter 4 
 
4.1 Results presentation 
 In the following chapter we will present the findings from the regression 
analysis, then proceed with commenting on them. Next, we will provide a 
comparison between the results of CSRHub database and then between the CSRHub 
results with KLD database and Accesstomedicineindex.org. 
 
4.2 CSRHub database regressions 
 In order to better utilize the data from CSRHub, we have broken down its 
data in 5 different ways. Therefore, we have used 5 different sets of independent 
variables, the first one consisting of the four variables, which are the scores of the 
four main categories (Community - Employees - Environment - Governance). The 
other 4 sets, each consists of 3 independent variables, which are the sub-categories 
of the main groups.  
 We will use as dependent variables the average stock price of the 
pharmaceutical firms under examination, as well as their average net income in 
million USD. This allows a better picture of what is significant for shareholders, as 
well as economic performance for companies, because sometimes stakeholders 
expectations might be different, as per agency problem.  
 The full results of each regression can be found in the appendix. We will 
present our findings in short and only focus on the variables that were statistically 
significant in each of the regression, interpreting the results as we believe is fit. 
 We have used monthly data between 2008 and 2013.  
 Please, review the following table for a better clarification of the 10 
regressions performed. 
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  Dependent variables 
Independent Variables 
 Average Stock Price Average Net Income 
a) Board 
b) Leadership Ethics 
c) Transparency and Reporting 
1a 1b 
a) Community Development & 
Philanthropy 
b) Human Rights & Supply Chain 
c) Product 
2a 2b 
a) Compensation and Benefits 
b) Diversity and Labor Rights 
c) Training, Safety and Health 
3a 3b 
a) Energy and Climate Change 
b) Environment Policy and 
Reporting 
c) Resource Management 
4a 4b 
a) Community 
b) Employees 
c) Environment 
d) Governance 
5a 5b 
Table 1: CSRHub data regression map. 
 
4.2.1 Common results between average stock price regressions and average net 
income regressions. 
 In this section we will present the findings that were common in the 
regressions with the same independent variables, but different dependent ones 
(average stock price and average net income). 
 One of the expected findings was that intercepts in every one of the ten 
different regression models were highly significant. This can be simply interpreted 
that our models might contain other significant variables, however as one could 
easily perceive in both cases the success or failure is driven mainly by other factors, 
that have little to do with practicing good social practices. Also, in absolute 
numerical terms each intercepts modifies the expected dependent variable more 
than all the independent variables combined, showing the intensity of the other 
factors (pricing, marketing, country's economy, etc.) not included in our models. 
 The second point of common ground derived from regressions 2a and 2b, 
where results have shown that the subcategory "Community Development & 
Philanthropy" had a slightly significant and positive results. It seems that companies 
that are more prone to providing part of their profits back into the community via 
donations or volunteerism manage not only to enhance their public image, which 
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can be portrayed in the stock price, but they also manage to increase their earnings. 
It seems that people are more willing to either invest or purchase goods from a 
company that helps the community. It is quite possible that they spend more easily 
thinking that a small part of the company's earnings will be returned to them via the 
community. As for the intensity of the effect in the case of average stock price for 
every 1 point increase in CSRHub score, the company increases its stock price by 0.24 
$ on average, however we should also point out that the significance of this variable 
was at a threshold with a t-stat of 1.65. On the other hand, it increases on average 
net income by 0.02 million $. 
 Next point of common result was in the "Resource Management" 
subcategory (regressions 4a-4b), where we can point out that in both cases, we had 
highly significant results with t-stats exceeding 2.576 and positive numbers. This 
category shows how efficient companies use resources at their disposal. This can be 
easily interpreted that a company from a CSR practice, also enjoys great economic 
benefits by enhancing its operations. Shortly that means less wastage, less costs. Our 
analysis has shown a 0.16$ increase in stock price and a whooping 1.16 million $ for 
every point increased in the CSRHub rating. 
 Last common results come from the main categories regression (5a-5b). 
Mainly derived from the subcategory "Resource Management", we can observe that 
the "Environment" category has a positive and highly significant result in both cases. 
Regression results show a 0.21$ increase in stock price on average and an expected 
increase of 1.09 million $ for every point increased in the CSRHub rating. We also 
observe a slightly significant and positive result in the category "Community", which 
again we could attribute to the subcategory "Community Development & 
Philanthropy" as we explained in our second point. Results are 0.31$ and 0.36 
million $ respectively. 
 We should also mention that the other subcategories examined in 
"Environment" and "Community" were insignificant in both cases, in addition to 
"Board" and " Training, Safety and Health" according to our results. 
 
4.2.2 Opposite results between average stock price regressions and average net 
income regressions. 
 In this section, we will present findings that were opposite either in regards to 
their significance level or their numerical sign. 
 Beginning with, all subcategories of "Governance" (regressions 1a-1b) were 
insignificant to net income. On the other hand in regards to stock price, our findings 
suggest a highly significant and positive relation with "Leadership Ethics", increasing on 
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average by 0.18$ the stock price for every point increased in the ranking. This 
subcategory measures relationship of the company with every stakeholder and the 
culture of ethical decision. It seems it drives the stock price up perhaps because people 
are more prone to investing in "good" rather than "evil" corporations and they seem to 
value being well informed in every step.  
 Another slightly significant, but negative this time subcategory in this regression 
is the "Transparency and Reporting". Our finding suggest that on average it lowers 
stock price by 0.11$ per point increased in CSRhub rating. This subcategory shows 
whether companies comply with certain CSR reporting standards and how those 
reports are made publicly available. Our thoughts on this peculiar result is that the 
decrease might have to do with the vast amount of money needed to prepare those 
reports and have them assured by an independent audit. It could maybe attributed 
to the general suspiciousness of the investing public in regards to the validity of 
those reports and how "independent" really is the 3rd party that audits them. 
  Next slightly significant variable comes up in the "Employees" category 
(regressions 3a-3b) for the net income dependent variable (subcategory 
"Compensation and Benefits" with a positive result. We can observe that on average 
companies increase their net income by 0.24 million $ for every increase in the 
rating. This shows as the name suggests, the financial and non-financial benefits a 
company provides to its employees. It seems that the higher the benefit for an 
employee the higher his/her appreciation for the company will be and thus his/her 
productivity. Also, higher employee retention rate allows for less expenses for 
recruiting and training costs. On the other hand, this variable is insignificant for stock 
price. 
 In the same category, in regards to subcategory "Diversity and Labor Rights" 
we come up with the only variable that is significant in both regressions, but has 
opposite sign. This subcategory portrays the fair treatment of employees, diversity 
policies, as well as respecting union practice rights (collective bargaining, right to 
organize), as well as their worker rights, i.e. minimum age of employment, forced 
labor, lack of discrimination. Regarding stock price, we observe a positive sign 
suggesting that for every 1 point of rating increased the company has an increased 
stock price of 0.18 $, whereas net income decreases by 0.19 million $ for every point 
increased. We believe that this difference has to do with the perception of a fair-
trade company by the stockholders, which increases stock price, even though this 
increase might not be explained in financial terms compared to similar companies. 
On the other hand, net income decreases, because the stronger the union of the 
company, then the more demanding it becomes. Also, public is aware of the colossal 
companies that employee children and unskilled labor in third countries and 
pharmaceutical industry would be no exception. It seems it has to do with being a 
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cost reduction measure which leads to a great competitive advantage in the 
nowadays fierce economic situations. 
 Concluding with the main categories regressions (5a-5b), we can observe that 
our findings suggest that "Governance" category is insignificant for net income, but 
slightly significant for stock price. It's result suggests that for a unit increase in the 
rating, the stock price will increase on average by 11 dollar cents. This can be 
portrayed by the appreciation of the communication between the company, the 
shareholders and the stakeholders in general. 
 Lastly, the "Employees" category is insignificant and statistically equal to 
zero, when regressed against stock price. On the other hand, our findings suggest 
that practicing good employee related CSR activities have a positive, but very close 
to zero effect (an increase of 0.01 million $ in expected on average for every point 
increase in the respective ranking). It seems that the two subcategories that drive 
the result, neutralize in a way each other with the positive effect of "Compensation 
and Benefits" subcategory slightly prevailing the "Diversity and Labor Rights" one. 
 
4.2.3 Other information and remarks 
 Adjusted R2 variants between 0.897 (or 8.97%) up to 0.1796 (or 17.96%), 
meaning our models fits the data by that percent. Even though, these numbers 
might seem quite low at first glance, in reality our models seem to fit the data 
sufficiently. At least the ones of the main categories, which are 0.1752 and 0.1796 
respectively. This remark comes when we compare our results to those of Ioannou I. 
and Serafeim G. (2014), who in their research provide results of various R-squares 
ranging from 0.174 up to 0.331. We need to stress out of course that CSR practices is 
a secondary (if that!) matter for most businesses, which focus and derive their 
results from other practices. 
 What we can conclude from these models is that practicing CSR does have a 
positive but rather moderate effect on businesses on average. Out of the 12 
subcategories, our results suggest that in regards to stock price 4 were significant 
and positive and 1 was significant and negative, while in regards to net income 3 
were significant and positive and 1 was significant and negative. However, our best 
fitted models, the ones in which we used the main categories ratings showed 3/4 
positive and significant in both cases. 
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4.3 KLD Data regression 
 In the following section we will present our findings in regards to KLD data 
regression. We have also used KLD data to regress the same variable in order to 
further validate CSRHub results with results from a wider accepted database. 
 We should note that in this case we will be working with data from 2008 up 
to 2012, unlike CSRHub data which were up to 2013. This difference has to do with 
data being unavailable at the time the research was written. Data are yearly, 
however they are numbered between 0 up to 5, most of which are between 0 and 1. 
For simplicity the few ratings above 1 have been changed to 1 and variables were 
treated as dummy variables. Non-rated companies were not taken into 
consideration for our calculations. 
 Another difference is that KLD data includes only data from USA companies. 
However, we were able to pair a total of 107 companies from our original data set 
and we used a total of 88 companies, which had available data in KLD database. 
 Our first step was to match the significant variables from CSRHub data to KLD 
available data. This was done in order to be able to have a comparison basis for the 
variables that we had some results. Then, we individually regressed each one of 
them to the according financial variable we wanted to compare (i.e. Governance 
category was regressed with stock price as dependent variable, but not with net 
income as it was insignificant in CSRHub data regressions). Of course, we could add 
two or more KLD categories for each CSRHub variable, however we believe that 
might cause co-linearity issues and the results will have a negligent difference. 
Therefore, our attempt was to pair CSRhub variable with the KLD category with the 
closest interpretation. 
 In the table below, one can see the pairing in detail. 
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   Dependent variables 
CSRHub (Sub)-
Category 
Independent Variables 
KLD Category Average Stock Price 
Average 
Net Income 
Leadership Ethics Political Accountability Strength 7a  
Transparency and 
Reporting Transparency Strength 7a  
Community 
Development & 
Philanthropy 
Generous Giving 8a 8b 
Compensation and 
Benefits Cash Profit Sharing  9b 
Diversity and Labor 
Rights Union Relations Strength 9a 9b 
Resource 
Management 
Beneficial Products & 
Services 10a 10b 
Governance 
Total Number of 
Corporate Governance 
Concerns 
11a  
Community Total Number of Community Strengths 11a 11b 
Employees 
Total Number of 
Employee Relations 
Concerns  
11b 
Environment Total Number of Environment Strengths 11a 11b 
Table 2: KLD data regression map paired with CSRHub variables. 
 
4.3.1 Regressions with common moderating effects between KLD and CSRHub 
datasets 
 In this sections we will present findings from our KLD regressions that their 
moderating effect on the dependant variable examined (stock price and net income) 
was similar to the equivalent regressions from CSRHub data. 
 To begin with, once again the intercepts in the regressions were significant. 
As we previously stated this is due to the fact that Corporate Social Responsibility is a 
secondary - if that - means for a company to succeed, even though our so far 
findings suggest a connection exists. 
 A company with "leadership ethics", as CSRhub names it, closely related to 
"political accountability" by KLD seems to enjoy a positive effect on its stock price. 
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On average companies that do get the point in KLD dataset have a higher stock price 
by 7.57$. 
 Next pairing with same effect in the community category is philanthropy. In 
order to get the point in this KLD category, companies have to spend more than 1.5% 
of their net earnings before taxes to charity. It seems that doing so suggest an 
average increase in their stock price by 9,29$ compared to the ones who don't (or 
spend less than that). 
 Continuing in the employee category, our findings suggest that there is a 
significant and positive relationship between profits shared between the employees. 
Paired with the compensation and benefits subcategory from CSRHub, we can also 
observe an increase in their net earnings of an average of 23,53 million USD, when 
compared to companies that don't. This is also a highly significant effect. 
 Finishing with the subcategories regressions, having innovative products, 
while efficiently promoting energy use is the subcategory we used from our KLD 
data. It seems that in both dependent variables, stock price and net earnings, the 
result suggest a positive and significant relation. On average stock price of 
companies that do use efficient energy management systems and innovation in their 
development and production enjoy an increased stock price by 6,54$, as well as 
12,63 million $ in profits. As commented already, this result is of no surprise, 
because less energy consumption would mean less cost, while innovative products 
and especially in the pharmaceutical industry is what allows them to mark-up at 
some extreme premiums. 
 To conclude with, our most interesting findings were when we paired the 
categories from CSRHub with the ones from KLD data. All of the independent 
variables we used, the total scores from main categories Community(both), 
Environment(both), Governance(stock price) and Employees(net earnings), our 
regression results suggest they are significant and with higher R2-Adjusted ratings 
than the CSRHub equivalents. More specifically, companies that scored in the KLD 
categories Governance, Community, Environment have an increased 12,86$, 22,34$ 
and 8,32$ stock price on average respectively when compared to the ones who 
don't. On the other hand, likewise on average companies enjoy an increase in their 
net earnings by 5,08 million $, 14,96 million $ and 4,13 million $, since categories 
Community, Employees, Environment all had significant t-test scores and positive 
signs. 
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4.3.2 Regressions with different moderating effects between KLD and CSRHub 
datasets 
 In the following section, we will examine our findings that suggest 
moderating effects on dependent variables were different between KLD and CSRHub 
datasets. 
 The first different result we came across was on the transparent reporting 
subcategories. In our CSRHub data regressions, our findings suggested a negative 
relation, however in our KLD dataset regression the result was a significant and 
positive variable, which shows us that companies that scored on this subcategory on 
average have a stock price of higher by 3.87$ compared to the ones that didn't. Our 
belief is that this difference has to do with how each rating is reported, meaning that 
the CSRHub subcategory for a higher mark requires alignment of the sustainability 
goals by management and employees, whereas the KLD score is given merely for 
excellent reporting in one field. Thus, we believe it is easier and cheaper for 
companies to acquire the mark from KLD and this is why our findings suggest a 
positive relation. 
 Another difference is in the "Generous Giving" subcategory, where our 
findings suggest a negative impact in the KLD dataset. Specifically, companies that 
scored in this category have decreased net earnings on average by 0,83 million $. 
However, we should note that when compared to the intercept the estimate is 
approximately 0.3% far less than the 1.5% needed to receive the marking in the 
subcategory. This difference could be attributed in tax exemptions or a general 
goodwill created around the charitable brand. 
 Lastly, we should mention that the pairings not mentioned above, according 
to our findings were insignificant and statistically equal to zero. 
 
4.3.3 Other information and remarks 
 R2 Adjusted scores in those regressions variant between 0.495 (or 4.95%) as 
high as 0,2408 (or 24.08%). As we already mentioned scores in this range are quite 
acceptable. Beginning with the lowest, we only meet a score lower than 13% in the 
subcategory employees, regressed against stock price, where the only variant, 
besides the intercept was insignificant. 
 On the other hand, R2 Adjusted scores were overall higher when compared to 
counterparts of the CSRHub dataset. It is important to note here that in both 
regressions, where we examined the main categories against the financial data, 
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scores were as high as 24.08% (stock price) and 22.75% (net earnings), which shows 
that the models fit our data particularly well. 
 
4.4 Accesstomedicineindex.org data regression 
 In the following section we will present our findings from regressing the 
accesstomedicineindex.org rankings against stock prices and net earnings. 
 Before, we provide our findings let's provide some information regarding the 
data, we will be using in this part. Accesstomedicineindex.org provides biannually a 
ranking of the top 20 pharmaceutical companies. Beginning in 2008, our data 
available is for 2010 and 2012 (by the time this part was written 2014 data were not 
yet announced). Accesstomedicineindex.org uses a scale of 0 to 5 in order to score 
those companies in several different categories (i.e. pricing, donations, 
management, etc.) and afterwards provides a ranking based on the scoring of those 
categories. 
 Unfortunately, exact data were unavailable from past years with the 
exception of the ranking. In order to better approximate our analysis, we have used 
linear interpolation to calculate the rankings for years 2009 and 2011. Afterwards, 
we used the data to regress the average stock price and average net earnings as 
dependant variables against the accesstomedicineindex.org ranking as independent 
variable. This was done in order to have another comparative basis for our results 
against CSRHub dataset. Since, subcategories data were unavailable our comparison 
will take place against the main categories regression as a whole. 
  Dependent variables 
Independent 
Variable
 
 Average Stock Price Average Net Income 
Accesstomedicineindex.org 
Ranking 12a 12b 
Table 3: Accesstomedicineindex.org data regression map 
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4.4.1 Accesstomedicineindex.org regression results 
 Alike previous regressions, we can observe that the intercept is highly 
significant. This is the same for both regressions, where the dependent variable is 
stock price and net income. 
 Regression 12a results suggest that there is an insignificant relation between 
the accesstomedicineindex.org ranking of the firms and the results on the stock 
exchange. Therefore, our findings suggest that the position on the ranking of the 
firms under discussion should result in no change in their stock market value. 
 On the other hand regression 12b results suggest that the is a slightly 
significant relation between the ranking of the firms and the results of their net 
earnings. The sign of the estimate is positive and shows that for every place higher in 
ranking the company is expected to increase their net earnings on average by 0,017 
billion $. Our data fit of the model is mediocre as the R2 Adjusted of 0,1431 (or 
14.31%) suggests. However, the estimate feels being a rather small number and very 
close to zero. When compared to CSRHub dataset, we can observe that its effect is 
on terms as for the positive sign, however the estimate is significantly lower. 
 
4.5 Chapter summary 
 In the 4th chapter, we have examined the results of the regressions using in 
order the datasets from CSRHub, KLD and Accesstomedicineindex.org. As CSRHub 
being the "main" dataset, the other two were used mainly to enhance the validity of 
the data and provide credibility of the results, thus were presented only in 
comparison to CSRHub and not as stand alone results. 
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Chapter 5 
 
5.1 Conclusions 
 As we conclude our research, the results provided us with a mixed set of 
interpretations. Our models contained both negative and positive results. However, 
as our findings suggest most of the independent variables examined had a positive 
moderating effect on the dependent ones. 
 More analytically, we have used a total of 49 different independent variables 
all of which were regressed against a total of 2 dependent variables, net earnings 
and stock price. Our results have suggested that there are 29 variables which were 
significant (as low as p<0.05 or higher on a two-tailed T-test). Of those 3 had a 
negative impact on the independent variables (approximately 10%), while the rest 
had a positive impact on the independent variables (approximately 90%).  
 Using these evidence, we can be assured that CSR initiatives in most cases do 
have a positive impact on the net earnings and the stock price of a company. Of 
course there are several other economic factors that could be examined in order to 
provide a more holistic view. However, we believe that those two variables under 
examination provide a viewpoint that covers a very wide range of a company's 
economic welfare, which is what their profit actually is and how the company 
economic and non-economic results are perceived by the investors. It seems that our 
study increases the bibliography that suggests a positive relationship between CSR 
initiatives and economic factors. 
 The real question though is in what extend do these initiatives assist the 
company in the sense of absolute numbers. In order to better portray the results, we 
assume that the intercept in each regression is translated as all the rest economic 
and non-economic factors that contribute in the independent factors. The table we 
have compiled below shows each of the significant variables and how would they 
add or decrease the dependant variables under examination. To provide a better 
explanation, this shows us that i.e. for every point a company increases their rating 
in Leadership and Ethics subcategory in the CSRHub rating system would result in a 
0,17% increase in the stock price. 
 
 
 
 
 
 
31 
 
Variable % per point 
Maximum 
% Variable 
% per 
point 
Maximum 
% 
Stock Price Net Income 
CSRHub results 
LeadEth 0,17% 10,34%       
TransRep -0,11% -6,32% CompBen 0,11% 6,54% 
ComPhil 0,26% 15,79% ComPhil 0,01% 0,68% 
DivLabor 0,25% 15,13% DivLabor -0,09% -5,18% 
ResMng 0,13% 7,58% ResMng 0,60% 36,25% 
Governance 0,12% 7,14% Community 0,13% 8,09% 
Community 0,34% 20,13% Employees 0,01% 0,45% 
Environment 0,23% 13,64% Environment 0,41% 24,49% 
KLD Results 
CGOV-str-E 5,37%   COM-str-A -0,30%   
CGOV-str-D 2,75%   EMP-str-C 9,09%   
COM-str-A 7,05%   ENV-str-A 4,79%   
ENV-str-A 4,74%         
CGOV-con-
Total 
11,21%   COM-str-
Total 
2,02%   
COM-str-Total 19,47%   EMP-con-
Total 
5,96%   
ENV-str-Total 7,25%   ENV-str-Total 1,65%   
Accesstomedicineindex.org Results 
ATMI 0,30% 6,09%       
Table 4: Variables impact on Intercept. 
 
 As we can see on Table 4 above, we have calculated the % change per point 
increase between the significant variables and the respective intercept in the 
regression. The column maximum represents the "% per point" column multiplied by 
60 in CSRHub results and multiplied by 20 in the Accesstomedicineindex.org results. 
This would give us an idea of how much would be the maximum increase (decrease) 
if a company increased the CSRHub rating by 20 up to 80 points, which are the two 
limits of our dataset or their ranking in the Accesstomedicineindex.org ranking from 
the last position (20) to the first one. KLD results do not have an equivalent 
multiplication since the data was used as a dummy variable. 
 These results show that despite variables having a positive impact, the 
absolute number or estimate when expressed in a percentage compared to the 
intercept seems to be rather small or negligent. Being, for example, a charitable 
company might net you a 15,79% increase in your stock price, but this scenario 
demands your company taking a complete change in the CSR initiative. That is 
climbing from the last spot to the first one, which would be a rather time-consuming 
feat, if possible to happen. 
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 We believe that CSR initiatives do assist in economic thriving for the 
companies, however this has to do with the size of the company and its current 
financial strength. Obviously, a struggling company should rather focus on other 
matters and have CSR as a secondary if that factor to take into consideration. 
 Our expects are for more companies to undertake such CSR initiatives. 
However, that has to be done for the correct reasons, i.e. wanting to help the less 
fortunate people in the developing countries and not to create a goodwill for 
potential  fines or just to add another publicity stunt in their arsenal. 
  
5.2 Limitations of the study 
 The most important limitation of the study has to do with the sample size. 
More specifically, the data used was dated after 2008, which means that we only 
took into consideration post-crisis data.  
 Another issue that had to do with our sample size was that even though the 
original sample (CSRHub data) contained companies from all around the globe, USA 
companies were clearly overrepresented. Also, in our KLD data, the companies we 
used to validate CSRHub results came only from USA companies. 
  Another limitation that had to do with our set of data is the biased nature of 
the publisher. We are certain that those companies do their best in order to 
interpret the initiatives in a score or a ranking in an as much objective as possible 
way, however since they do not deal with raw numbers, such as profits or number of 
employees, errors and omits are bound to exist. 
 As part of an MSC course completion, the time available for the conduction of 
this research was rather limited. If more time was available, we would be able to 
better represent our results and conduct regressions within regressions by using 
further classification of the companies (i.e. size, country, profitability and so on). 
 Lastly, as mentioned during our bibliographical research, there is no research 
framework in regards to CSR related researches. Therefore, all of our regressions and 
interpretations were done under researchers crisis.  
 
5.3 Further research 
 As limitations of the study suggest, there are grounds for further research 
with data from pre-2008 years, as well as with a focus on pharmaceuticals outside 
USA or to provide further research when it has to do with the size of the company or 
their origin and so on. 
 Except for the pharmaceutical sector one could focus on providing sector-
specific research on CSR initiatives, since most of the researches we have identified 
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in our bibliographical research had to do with companies in total and were not 
divided based on their sector. 
 Lastly, case studies with initiatives and their results after a set amount of 
time, i.e. after 1 and 2 years, could be very interesting in the pharmaceutical field. 
 
5.4 Chapter summary 
 During the 5th and last chapter of our research, we have provided the 
conclusions of our research, based on our findings. We have also presented the 
limitations of our study, as well as possible grounds for further research. 
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Appendix 
 
CSRHub regression analysis results 
 
Regression 1a - Governance subcategories / Average stock price dependant value 
Coefficients Estimates Standard Error t-stat Collinearity statistics 
Notations β SE t Tol VIF 
Intercept 104,4*** 22,37 22,46     
Board 0,14 0,03 0,99 0,824 1,2136 
LeadEth 0,18*** 0,04 14,32 0,680 1,4706 
TransRep  -0,11* 0,03 1,77 0,984 1,0163 
            
Observations 3528         
R-Square 0,1684         
R-Adjusted 0,1677         
* p<0.05, ** p<0.01, *** p<0.001         
 
 
 
Regression 2a - Community subcategories / Average stock price dependant value  
Coefficients Estimates Standard Error t-stat Collinearity statistics 
Notations β SE t Tol VIF 
Intercept 91,52*** 18,28 24,13     
ComPhil 0,24* 0,07 1,65 0,661 1,5129 
Product 0,27 0,12 0,84 0,688 1,4535 
HRSupCh 0,15 0,04 1,41 0,858 1,1655 
           
Observations 3528         
R-Square 0,1456       
R-Adjusted 0,1449         
* p<0.05, ** p<0.01, *** p<0.001         
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Regression 3a - Employees subcategories / Average stock price dependant value 
Coefficients Estimates Standard Error t-stat Collinearity statistics 
Notations β SE t Tol VIF 
Intercept 71,19*** 27,45 18,99     
CompBen -0,10 0,02 0,29 0,771 1,2970 
DivLabor 0,18* 0,06 1,78 0,794 1,2594 
TrainSafHeal 0,25 0,05 0,11 0,713 1,4025 
            
Observations 3528         
R-Square 0,0905         
R-Adjusted 0,0897         
* p<0.05, ** p<0.01, *** p<0.001         
 
 
 
Regression 4a - Environment subcategories / Average stock price dependant value 
Coefficients Estimates Standard Error t-stat Collinearity statistics 
Notations β SE t Tol VIF 
Intercept 126,11** 26,12 2,11     
EneClim 0,13 0,03 1,32 0,675 1,4815 
PolRep 0,20 0,04 0,89 0,981 1,0194 
ResMng 0,16*** 0,03 12,57 0,928 1,0776 
            
Observations 3528         
R-Square 0,1145         
R-Adjusted 0,1137         
* p<0.05, ** p<0.01, *** p<0.001         
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Regression 5a - Main categories / Average stock price dependant value 
Coefficients Estimates Standard Error t-stat Collinearity statistics 
Notations β SE t Tol VIF 
Intercept 92,54*** 31,83 32,54     
Governance 0,11* 0,01 1,68 0,554 1,8051 
Community 0,31* 0,08 1,74 0,768 1,3021 
Employees 0,17 0,04 1,22 0,842 1,1876 
Environment 0,21*** 0,04 8,65 0,728 1,3736 
            
Observations 4704         
R-Square 0,1759         
R-Adjusted 0,1752         
* p<0.05, ** p<0.01, *** p<0.001         
 
 
 
Regression 1b - Governance subcategories / Average net income dependant value 
Coefficients Estimates Standard Error t-stat Collinearity statistics 
Notations β SE t Tol VIF 
Intercept 233,89*** 71,14 8,86     
Board 0,55 0,13 1,80 0,874 1,1442 
LeadEth -0,21 0,04 1,02 0,730 1,3699 
TransRep -0,41 0,10 0,76 0,963 1,0384 
            
Observations 3528         
R-Square 0,1286         
R-Adjusted 0,1279         
* p<0.05, ** p<0.01, *** p<0.001         
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Regression 2b - Community subcategories / Average net income dependant value 
Coefficients Estimates Standard Error t-stat Collinearity statistics 
Notations β SE t Tol VIF 
Intercept 176,95*** 54,91 41,50     
ComPhil 0,02* 0,01 1,82 0,711 1,4065 
Product 0,33 0,09 1,70 0,738 1,3550 
HRSupCh -0,14 0,05 1,15 0,908 1,1013 
            
Observations 3528         
R-Square 0,1711         
R-Adjusted 0,1704         
* p<0.05, ** p<0.01, *** p<0.001         
 
 
 
Regression 3b - Employees subcategories / Average net income dependant value 
Coefficients Estimates Standard Error t-stat Collinearity statistics 
Notations β SE t Tol VIF 
Intercept 220,67*** 72,20 7,66     
CompBen 0,24** 0,04 2,04 0,821 1,2180 
DivLabor  -0,19*** 0,10 3,14 0,844 1,1848 
TrainSafHeal 0,58 0,15 1,57 0,763 1,3106 
            
Observations 3528         
R-Square 0,1055         
R-Adjusted 0,1047         
* p<0.05, ** p<0.01, *** p<0.001         
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Regression 4b - Environment subcategories / Average net income dependant value 
Coefficients Estimates Standard Error t-stat Collinearity statistics 
Notations β SE t Tol VIF 
Intercept 191,23*** 80,04 8,84     
EneClim 0,53 0,21 1,15 0,725 1,3793 
PolRep 0,39 0,11 1,42 0,875 1,1429 
ResMng 1,16*** 0,38 6,33 0,978 1,0225 
            
Observations 3528         
R-Square 0,1398         
R-Adjusted 0,1391         
* p<0.05, ** p<0.01, *** p<0.001         
 
 
 
 
Regression 5b - Main categories / Average net income dependant value 
Coefficients Estimates Standard Error t-stat Collinearity statistics 
Notations β SE t Tol VIF 
Intercept 267,45*** 43,72 14,04     
Governance 0,64 0,20 0,56 0,604 1,6556 
Community 0,36* 0,12 1,81 0,818 1,2225 
Employees  0,02** 0,00 2,10 0,892 1,1211 
Environment 1,09*** 0,34 4,59 0,778 1,2853 
            
Observations 4704         
R-Square 0,1803         
R-Adjusted 0,1796         
* p<0.05, ** p<0.01, *** p<0.001         
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KLD  regression analysis results 
 
Regression 7a - Governance subcategories / Average stock price dependant value 
Coefficients Estimates Standard Error t-stat Collinearity statistics 
Notations β SE t Tol VIF 
Intercept 140,88* 26,47 1,77     
CGOV-str-E 7,57** 2,34 2,02 0,764 1,3089 
CGOV-str-D 3,87* 1,01 1,93 0,847 1,1806 
            
Observations 880         
R-Square 0,1354         
R-Adjusted 0,1334         
* p<0.05, ** p<0.01, *** p<0.001         
 
Regression 8a - Community subcategories / Average stock price dependant value 
Coefficients Estimates Standard Error t-stat 
Notations β SE t 
Intercept 131,82** 19,44 2,05 
COM-str-A 9,29* 2,64 1,87 
        
Observations 440     
R-Square 0,1863   
R-Adjusted 0,1844     
* p<0.05, ** p<0.01, *** p<0.001     
 
Regression 9a - Employees subcategories / Average stock price dependant value 
Coefficients Estimates Standard Error t-stat 
Notations β SE t 
Intercept 124,19** 33,17 2,17 
EMP-str-A 15,18 2,19 1,38 
    
Observations 440     
R-Square 0,0517     
R-Adjusted 0,0495     
* p<0.05, ** p<0.01, *** p<0.001     
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Regression 10a - Environment subcategories / Average stock price dependant value 
Coefficients Estimates Standard Error t-stat 
Notations β SE t 
Intercept 138,01*** 22,96 14,48 
ENV-str-A 6,54** 0,98 2,30 
        
Observations 440     
R-Square 0,1342     
R-Adjusted 0,1322     
* p<0.05, ** p<0.01, *** p<0.001     
 
 
Regression 11a - Main categories / Average stock price dependant value 
Coefficients Estimates Standard Error t-stat Collinearity statistics 
Notations β SE t Tol VIF 
Intercept 114,75** 14,94 2,47     
CGOV-con-
Total 
12,86** 2,47 2,52 0,679 1,4728 
COM-str-Total 22,34* 5,31 1,84 0,597 1,6750 
ENV-str-Total 8,32** 0,43 2,24 0,614 1,6287 
            
Observations 1320         
R-Square 0,2425         
R-Adjusted 0,2408         
* p<0.05, ** p<0.01, *** p<0.001         
 
Regression 8b - Community subcategories / Average net income dependant value 
Coefficients Estimates Standard Error t-stat 
Notations β SE t 
Intercept 284,11* 73,17 1,83 
COM-str-A  -0,86* 0,52 1,94 
        
Observations 440     
R-Square 0,1754     
R-Adjusted 0,1735     
* p<0.05, ** p<0.01, *** p<0.001     
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Regression 9b - Employees subcategories / Average net income dependant value 
Coefficients Estimates Standard Error t-stat Collinearity statistics 
Notations β SE t Tol VIF 
Intercept 258,88** 38,84 1,99     
EMP-str-C 23,53*** 5,05 8,46 0,914 1,0941 
EMP-str-A -4,96 1,32 0,76 0,857 1,1669 
            
Observations 880         
R-Square 0,1468         
R-Adjusted 0,1449         
* p<0.05, ** p<0.01, *** p<0.001         
 
Regression 10b - Environment subcategories / Average net income dependant value 
Coefficients Estimates Standard Error t-stat 
Notations β SE t 
Intercept 263,50** 51,73 2,19 
ENV-str-A 12,63*** 2,08 11,43 
        
Observations 440     
R-Square 0,1423     
R-Adjusted 0,1403     
* p<0.05, ** p<0.01, *** p<0.001     
 
Regression 11b - Main categories / Average net income dependant value 
Coefficients Estimates Standard Error t-stat Collinearity statistics 
Notations β SE t Tol VIF 
Intercept 251,03*** 44,12 22,43     
COM-str-
Total 
5,08* 1,07 1,81 0,778 1,2853 
EMP-con-
Total 
14,96* 2,34 1,95 0,924 1,0823 
ENV-str-Total 4,13** 0,84 2,36 0,843 1,1862 
            
Observations 1320         
R-Square 0,2293         
R-Adjusted 0,2275         
* p<0.05, ** p<0.01, *** p<0.001         
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Accesstomedicineindex.org regression analysis results 
 
Regression 12a - Ranking / Average stock price dependant value 
Coefficients Estimates Standard 
Error 
t-stat 
Notations β SE t 
Intercept 169,01*** 44,56 8,97 
ATMI 5,33 1,32 1,52 
        
Observations 100     
R-Square 0,1457     
R-Adjusted 0,1370     
* p<0.05, ** p<0.01, *** p<0.001   
 
 
 
Regression 12b - Ranking / Average net income dependant value 
Coefficients Estimates Standard 
Error 
t-stat 
Notations β SE t 
Intercept 5,58*** 0,84 13,76 
ATMI 0,017* 0,004 1,78 
        
Observations 100     
R-Square 0,1518     
R-Adjusted 0,1431     
* p<0.05, ** p<0.01, *** p<0.001   
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